prikaz prve stranice dokumenta Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
  Preuzmi
PDF 1.14 MB
Znanstveni rad - Izvorni znanstveni rad
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Bone Marrow Transplantation, 59 (2024), 6; 803-812. https://doi.org/10.1038/s41409-024-02248-9
Passweg, Jakob R.; Baldomero, Helen; Ciceri, Fabio; de la Cámara, Rafael; Glass, Bertram; Greco, Raffaella; Hazenberg, Mette D.; Kalwak, Krzysztof; McLornan, Donal P.; Neven, Bénédicte; Perić, Zinaida; Risitano, Antonio M.; Ruggeri, Annalisa; Snowden, John A.; Sureda, Anna Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Passweg, J. R., Baldomero, H., Ciceri, F., de la Cámara, R., Glass, B., Greco, R. ... Sureda, A. (2024). Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation, 59. (6), 803-812. doi: 10.1038/s41409-024-02248-9

Passweg, Jakob R., et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT." Bone Marrow Transplantation, vol. 59, br. 6, 2024, str. 803-812. https://doi.org/10.1038/s41409-024-02248-9

Passweg, Jakob R., Helen Baldomero, Fabio Ciceri, Rafael de la Cámara, Bertram Glass, Raffaella Greco, Mette D. Hazenberg, et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT." Bone Marrow Transplantation 59, br. 6 (2024): 803-812. https://doi.org/10.1038/s41409-024-02248-9

Passweg, J. R., et al. (2024) 'Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT', Bone Marrow Transplantation, 59(6), str. 803-812. doi: 10.1038/s41409-024-02248-9

Passweg JR, Baldomero H, Ciceri F, de la Cámara R, Glass B, Greco R, i sur.. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation [Internet]. 06.2024. [pristupljeno 02.12.2024.];59(6):803-812. doi: 10.1038/s41409-024-02248-9

J. R. Passweg, et al., "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT", Bone Marrow Transplantation, vol. 59, br. 6, str. 803-812, Lipanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:286040. [Citirano: 02.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:286040
Podaci o radu
Naslov (engleski)Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
AutorJakob R. Passweg
AutorHelen Baldomero
AutorFabio Ciceri
AutorRafael de la Cámara
AutorBertram Glass
AutorRaffaella Greco
AutorMette D. Hazenberg
AutorKrzysztof Kalwak
AutorDonal P. McLornan
AutorBénédicte Neven
AutorZinaida Perić
AutorAntonio M. Risitano
AutorAnnalisa Ruggeri
AutorJohn A. Snowden
AutorAnna Sureda
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (−4.0%) and autologous HCT (−1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26.2%) and non-malignant disorders (2572; 14.4%). Main indications for autologous HCT were lymphomas (7897; 32.9%), PCD (13,694; 57.1%) and solid tumors (1593; 6.6%). In allogeneic HCT, use of sibling donors decreased by −7.7%, haploidentical donors by −6.3% and unrelated donors by −0.9%. Overall cord blood HCT decreased by −16.0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBone Marrow Transplantation
Brojčani podacivol. 59, br. 6, str. 803-812
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-024-02248-9
URN:NBNurn:nbn:hr:105:286040
Datum objave publikacije2024-06
URL dokumentahttps://www.nature.com/articles/s41409-024-02248-9
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-11-11 09:34:16